IB
ALNY icon

Intrust Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Intrust Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
737
+132
+22% +$39.8K 0.02% 397
2026
Q1 		$200K Buy
605
+67
+12% +$22.8K 0.02% 405
2025
Q4 		$214K Buy
+538
New +$238K 0.02% 377

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Intrust Bank's ALNY Position: Q2 2026 in Review

Intrust Bank increased its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q2 2026, buying an estimated $39.8K and bringing the position to 737 shares worth $222K. The position accounts for 0.02% of the portfolio, ranked #397.

Intrust Bank first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Intrust Bank held 737 shares of Alnylam Pharmaceuticals worth $222K as of Q2 2026.
  • Intrust Bank bought 132 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $39.8K.
  • Alnylam Pharmaceuticals made up 0.02% of Intrust Bank's portfolio in Q2 2026, its #397 holding.
  • Intrust Bank first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Intrust Bank's 13F filing for Q2 2026, filed 5 Aug 2026.